Michael R. Megna - Oct 4, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Oct 4, 2023
Transactions value $
-$833
Form type
4
Date filed
10/6/2023, 04:26 PM
Previous filing
Sep 6, 2023
Next filing
Dec 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +175 +1.04% 17.1K Oct 4, 2023 Direct F1
transaction KNSA Class A Common Share Tax liability -$833 -52 -0.3% $16.01 17K Oct 4, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -175 -33.33% $0.00 350 Oct 4, 2023 Class A Common Share 175 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.